Last reviewed 2026-04-20 · How we verify

KTE-X19

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Pyrexia
• Anaemia
• Platelet count decreased
• Chills
• CYTOKINE RELEASE SYNDROME
• Hyponatraemia
• Diarrhoea
• Fatigue
• Neutrophil count decreased
• Weight decreased
• White blood cell count decreased
• Hypoalbuminaemia

Key clinical trials

• Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) (PHASE2)
• Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (PHASE2)
• Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
• Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) (PHASE2)
• A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma (PHASE2)
• Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (PHASE2)
• Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (PHASE2)
• Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• KTE-X19 CI brief — competitive landscape report
• KTE-X19 updates RSS · CI watch RSS
• Kite, A Gilead Company portfolio CI